How lung fibrosis affects cancer immunity and treatment effectiveness
Official title: Lung fibrosis impairs tumor immunity and limits immune checkpoint efficacy
Funded at Washington University · NIH-11113930 · Data updated 2026-11-12
This study is looking at how lung fibrosis affects the immune system's ability to fight lung cancer, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 12, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $231,870 |
| NIH project number | 5K08CA282968-02 |
| Project ID | NIH-11113930 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung cancer who also have lung fibrosis.
✕Less likely to help
Patients without lung cancer or those whose lung conditions do not involve fibrosis may not benefit from this research.
What this research studies
This research investigates the relationship between lung fibrosis and the immune system's ability to fight lung cancer. The principal investigator, with a strong background in biochemistry and oncology, aims to understand how lung fibrosis impairs tumor immunity and limits the effectiveness of immune checkpoint therapies. By utilizing advanced techniques in molecular profiling and computational biology, the research will explore new ways to enhance anti-cancer immunotherapy. Patients may benefit from insights that could lead to improved treatment strategies for lung cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for lung cancer patients with lung fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding the tumor microenvironment's role in cancer immunity, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Herzog, Brett Howard — Washington University
- Study coordinator: Herzog, Brett Howard
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.